- Nuvalent (NUVL, Financial) to present at the 2025 ASCO Annual Meeting from May 30 to June 5.
- ALKAZAR Phase 3 trial to compare neladalkib with ALECENSA® for ALK-positive NSCLC.
- HEROEX-1 trial evaluates safety of NVL-330 for HER2-altered NSCLC.
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company, is set to present two 'Trial in Progress' posters at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, scheduled from May 30 to June 5, 2025. The presentations will focus on the company's advancements in targeted cancer therapies.
The first presentation will cover the ALKAZAR trial (NCT06765109), a global Phase 3 study aimed at evaluating the efficacy of neladalkib, a novel ALK-selective inhibitor, compared with the current standard of care ALECENSA® (alectinib) in TKI-naïve ALK-positive non-small cell lung cancer (NSCLC) patients. This randomized controlled trial will assign patients 1:1 to either treatment option and is set to commence in the first half of 2025.
Additionally, the second presentation will discuss the ongoing HEROEX-1 Phase 1a/1b trial (NCT06521554) for NVL-330, a HER2-selective tyrosine kinase inhibitor. The study is focused on assessing the safety and tolerability of NVL-330 in pre-treated patients with HER2-altered NSCLC. Primary objectives include determining the recommended Phase 2 dosing, characterizing the pharmacokinetics, and evaluating preliminary anti-tumor efficacy.
Nuvalent continues to leverage its expertise in chemistry and structure-based drug design to develop therapies aimed at overcoming the limitations of existing treatments, offering new hope to patients with challenging cancer diagnoses.
